Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. (4th May 2019)

• Record Type: Journal Article
• Authors: Popinat, Geoffrey; Cousse, Stéphanie; Goldfarb, Lucas; Becker, Stéphanie; Gardin, Isabelle; Salaün, Mathieu; Thureau, Sébastien; Vera, Pierre; Guisier, Florian; Decazes, Pierre
• Is Part Of: Oncoimmunology. Volume 8:Number 5(2019)
• Publication Date: 2019-05-04
• Subjects: Body composition -- immunotherapy -- positron emission tomography -- computed tomography -- prognostic factor -- predictive factor -- nuclear medicine -- non-small cell lung carcinoma -- personalized medicine -- nivolumab; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2019.1580128
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Introduction : Our aim was to explore the prognostic value of anthropometric parameters in patients treated with nivolumab for stage IV non-small cell lung cancer (NSCLC). Methods : We retrospectively included 55 patients with NSCLC treated by nivolumab with a pretreatment 18 FDG positron emission tomography coupled with computed tomography (PET/CT). Anthropometric parameters were measured on the CT of PET/CT by in-house software (Anthropometer3D) allowing an automatic multi-slice measurement of Lean Body Mass (LBM), Fat Body Mass (FBM), Muscle Body Mass (MBM), Visceral Fat Mass (VFM) and Sub-cutaneous Fat Mass (SCFM). Clinical and tumor parameters were also retrieved. Receiver operator characteristics (ROC) analysis was performed and overall survival at 1 year was studied using Kaplan–Meier and Cox analysis. Results : FBM and SCFM were highly correlated (ρ = 0.99). In ROC analysis, only FBM, SCFM, VFM, body mass index (BMI) and metabolic tumor volume (MTV) had an area under the curve (AUC) significantly higher than 0.5. In Kaplan-Meier analysis using medians as cut-offs, prognosis was worse for patients with low SCFM (<5.69 kg/m 2 ; p = 0.04, survivors 41% vs 75%). In Cox univariate analysis using continuous values, BMI (HR = 0.84, p = 0.007), SCFM (HR = 0.75, p = 0.003) and FBM (HR = 0.80, p = 0.004) were significant prognostic factors. In multivariate analysis using clinical parameters (age, gender, WHO performance status, number prior regimens) and SCFM, only SCFM was significantly associated with poor survival (HR = 0.75, p = 0.006). Conclusions : SCFM is a significant prognosis factor of stage IV NSCLC treated by nivolumab.